Evidence map›Paper›PMID 42524709›Full record

ArticleThe Journal of international medical research2026

Exploring the landscape of programmed cell death protein-1 and cluster of differentiation 28 positive T cells and cytokines in non-small cell lung cancer: A retrospective case-control study.

Ying Yang, Rui-Cheng Li, Changkun Lyu, Weibin Zhang, Yanmin Sun, Ran Xie

Abstract read
In one paragraph

Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying YangSchool of Medical Technology, Shangqiu Medical College, China.ORCID 0009-0007-0077-5622
Rui-Cheng LiDepartment of Clinical Laboratory, Tangdu Hospital, Fourth Military Medical University, China.ORCID 0000-0003-4857-3716
Changkun LyuSchool of Medical Technology, Shangqiu Medical College, China.ORCID 0000-0002-8278-5766
Weibin ZhangSchool of Medical Technology, Shangqiu Medical College, China.ORCID 0009-0001-5785-3982
Yanmin SunSchool of Medical Technology, Shangqiu Medical College, China.ORCID 0009-0001-1623-0877
Ran XieSchool of Medical Technology, Shangqiu Medical College, China.ORCID 0009-0005-9655-3164

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveProgrammed cell death protein-1 (PD-1) and cluster of differentiation (CD) 28 (CD28) are representative stimulatory and inhibitory signals that regulate T cell function. This retrospective study aimed to evaluate alterations in peripheral PD-1- and CD28-positive T cell populations in patients with benign pulmonary nodules and non-small cell lung cancer (NSCLC).MethodsKaplan-Meier plotter was used to analyze the prognostic value of PD-1 and CD28 expression in NSCLC. Flow cytometry was used to detect T cell subsets in peripheral blood. Serum tumor markers were detected using a chemiluminescent analyzer. Cytokine levels were detected by Cytometric Bead Array.ResultsA total of 526 patients with NSCLC (early stage: 251; advanced stage: 275), 55 patients with benign pulmonary nodules, and 33 healthy participants were included. Kaplan-Meier plotter analysis showed that higher PD-1 expression was correlated with poorer survival in patients with lung adenocarcinoma), whereas higher CD28 expression was correlated with favorable survival in patients with lung adenocarcinoma and lung squamous cell carcinoma. Compared with healthy controls, the proportion and number of peripheral PD-1+CD3+ T cells and PD-1+CD4+ T cells were significantly increased in patients with benign pulmonary nodules and NSCLS. The numbers of CD28+CD3+ T cells and CD28+CD4+ T cells were lower in patients with NSCLC than in healthy controls. Notably, there were no differences in PD-1+ or CD28+ T cells between patients with benign pulmonary nodules and NSCLC. The numbers of PD-1+ and CD28+ T cells were lower in patients with advanced NSCLC than in those with early NSCLC. Additionally, the levels of serum tumor markers (carcinoembryonic antigen, neuron-specific enolase, cancer antigen 125, cytokeratin 19 fragment antigen 21-1, and cancer antigen 50) were not different between patients with benign pulmonary nodules and early NSCLC but were higher in patients with advanced NSCLC. Moreover, serum interleukin 6 and interferon-γ levels were higher in patients with advanced NSCLC than in those with benign pulmonary nodules and early NSCLC.ConclusionIncreased PD-1 and decreased CD28 suggest potential T cell dysfunction in patients with benign pulmonary nodules and NSCLC. Patients with benign pulmonary nodules showed characteristics similar to those of patients with early NSCLC with respect to PD-1+/CD28+ T cells, tumor markers, and cytokines.

Indexed as

Carcinoma, Non-Small-Cell LungCD28 AntigensCytokinesLung NeoplasmsProgrammed Cell Death 1 ReceptorT-LymphocytesAdultAgedBiomarkers, TumorCase-Control StudiesFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorCD28 AntigensCytokinesPDCD1 protein, humanProgrammed Cell Death 1 Receptorbenign pulmonary nodulecluster of differentiation 28cytokinesnon-small cell lung cancerProgrammed cell death protein-1

Identifiers

PMID42524709
PMCPMC13424782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.